Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation.

Summary: Melanoma is a dangerous type of skin cancer. Sometimes, standard treatments stop working, so doctors need new ways to fight it. In this study, scientists looked at a special protein called IL13Rα2 that is found on the surface of some advanced melanoma cells. They created a new medicine—a "bispecific T-cell engager" (BTE)—that acts like a bridge. It connects the cancer cells directly to the body's own immune cells (T cells). This bridge helps the immune cells find, attack, and destroy the cancer. In tests on lab cells and in mice, this new medicine successfully shrank tumors by bringing more active immune cells into the cancer. This could be a very promising new treatment for people with advanced skin cancer!